Humanized antibodies as potential therapeutic drugs

Annals of Allergy, Asthma and Immunology

Volumn 81, Issue 2, 1998, Pages 105-116

  Vaswani, Surender K ^a,b   Hamilton, Robert G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BETA1 INTEGRIN; CGP 51901; CHIMERIC ANTIBODY; ERYTHROCYTE ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 5; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC DISEASE; ANAPHYLAXIS; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; CANCER; CLINICAL TRIAL; GENETIC ENGINEERING; HUMAN; HYBRIDOMA; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFECTION; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; VIRUS INFECTION;

EID: 0031665064     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62794-9     Document Type: Review

References (102)

1. Von Behring E, Kitasato S. Ueber das Zustandekommen der Diphentherie-Immunitat und der Tetanus-Immunitat bei Thieren. Dtsch Med Wochenschr 1890;16:1113.
2. Haber E. Engineered antibodies as pharmacological tools. Immunol Rev 1992;130:189-212.
3. Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol Today 1993;44: 421-425.
4. Levy R, Miller RA. Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Ann Rev Med 1983;34:107-116.
5. Hamilton RG, Sun L, Beall PT. Production and quality control of monoclonal antibody reagents and drugs. In: Moulds JM, Mascuredis SP, eds. Monoclonal antibodies. Arlington, VA: American Association of Blood Banks, 1989:89-90.
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
7. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985;135:1530-1535.
8. LoBuglio AP, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4224.
9. Miller RA, Oseroff AR, Stratte PT, Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983;62: 988-995.
10. LoBuglio AF, Salch M, Peterson L, et al. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 1986;5:S117-123.
11. Morrell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970;49: 673-680.
12. Shearman CW, Pollock D, White G, et al. Construction, expression and characterization of humanized antibodies directed against the human A/β T cell receptor. J Immunol 1991; 147(12):4366-4373.
13. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988;65:329-335.
14. James K, Boyd JE, Micklem LR, et al. Monoclonal antibodies, their production and potential in clinical practice. Scottish Med J 1984;29(2): 67-83.
15. Carson DA, Friemark BD. Human lymphocyte hybridomas and monoclonal antibodies. Adv Immunol 1986;38:275-311.
16. Morrison SL. Transfectomas provide novel chimeric antibodies. Science 1985;229:1202-1207.
17. Oi VT, Morrison SL, Herzenberg LA, Berg P. Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci USA 1983; 80:825-829.
18. Neuberger MS, Williams GT, Mitchell EB, et al. A hapten specific chimeric IgE antibody with human physiological effector function. Nature 1985;314:268-470.
19. Morrison SL, Oi VT. Genetically engineered antibody molecules. Adv Immunol 1989;44:65-92.
20. Liu AY, Robinson RR, Hellstrom KE, et al. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 1987;84:3439-3443.
21. Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351-1361.
22. Gorman SD, Clark MR. Humanization of monoclonal antibodies for therapy. Sem Immunol 1990;2: 457-466.
23. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992;130: 5-39.
24. Duncan AR, Woof JM, Partidge LJ, et al. Localization of the binding site for the human high affinity Fc receptor on IgG. Nature 1988;332: 563-564.
25. Woodle ES, Thistlethwaite JR, Jolliffe LK, et al. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 1992; 148:2756-2763.
26. Alegre ML, Collins AM, Pulito VL, et al. Effect of single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 1992;148:3461-3468.
27. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986;321:522-525.
28. Verhoeyen M, Milstein C, Winter G. Reshaping human antibodies: grafting an anti-lysozyme activity. Science 1988;239:1534-1536.
29. Riechmann L, Clark M, Waldmann, Winter G. Reshaping human antibodies for therapy. Nature 1988;332: 323-337.
30. Tempest PR, Bremner P, Lambert M, et al. Reshaping human monoclonal antibody to inhibit respiratory syncitial virus infection in vivo. Bio/Technol 1991;9:266-271.
31. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the human interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86:10029-10033.
32. Co MS, Deschamps M, Whitley RI, Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA 1991;88:2869-2873.
33. Co MS, Avdalovic NM, Caron PC, et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992;148: 1149-1154.
34. Mark GE, Silberklang M, Macintyre DE, et al. Derivation of therapeutically active humanized and veneered anti-CD18 antibodies. In: Metcalf BW, Dalton BJ, eds. Cellular adhesion: molecular definition to therapeutic potential. New York: Plenum Press, 1994:291-312.
35. Gussowal D, Seemann G. Humanization of monoclonal antibodies. Meth Enzymol 1991;203:99-121.
36. Taylor G, Furze J, Tempest PR, et al. Humanized monoclonal antibody to respiratory syncitial virus. Lancet 1991;337:1411-1412.
37. Tempest PR, Bremner P, Lambert M, et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncitial virus infection in vivo. Bio/Technol 1991;9:266-271.
38. Co MS, Avdalovic NM, Caron PC, et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992;148: 1149-1154.
39. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-pi85 HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89: 4285-4289.
40. Padlan EA. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 1991;28:489-498.
41. Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-1071.
42. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-277.
43. Presta LG, Lahr SJ, Sheilds RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151(5): 2623-2632.
44. Takai T, Yuuki, Yasue N, et al. Humanization of mouse anti-human high-affinity IgE receptor (FcεRI) monoclonal antibodies. J Allergy Clin Immunol 1997;S438.
45. Davis FM, Gossett LA, Pinkston KL, et al. Can anti-IgE be used to treat allergy? Springer Semin Immunopath 1993;15:51-73.
46. Chang TW, Davis FM, Sun NC, et al. Monoclonal antibodies specific for human IgE-producing B cells: A potential therapeutic for IgE-mediated allergic diseases. BioTech 1990;8: 122-126.
47. Kolbinger F, Saldanha J, Hardman N, Bendig MM. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Engineering 1993;6(8):971-980.
48. Dobrina A, Menegazzi R, Carlos TM, et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine induced endothelial ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. J Clin Invest 1991;88: 20-26.
49. Elices MJ, Osborn L, Takada et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990;60:577-584.
50. Vonderheide RH, Springer TA. Lymphocyte adhesion through very late antigen 4: evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional α 4 integrin counter-receptor on stimulated endothelium. J Exp Med 1992;175: 1433-1442.
51. Abraham WM, Sielczak MW, Ahmed A, et al. α 4-Intergins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. Am Soc Clin Invest 1993;93:776-787.
52. Vejlsgaard GL, Ralfkiaer E, Avnstorp C, et al. Kinetics and characterization of intercellular adhesion molecule-1 (ICAM-1) expression on keratinocytes in various inflammatory skin lesions and malignant cutaneous lymphomas. Am Acad Dermatol 1989;20:782-790.
53. Smith CW, Rothlein R, Hughes BJ, et al. Recognition of an endothelial determinant for CD18-dependent human neutrophil adherence and transendothelial migration. J Clin Invest 1988;82:1746-1756.
54. Wegner CD, Gundel RH, Reilly P, et al. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990;247:456-459.
55. Sanderson CJ, Campbell HD, Young IG. Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells. Immunol Rev 1988;102:29-50.
56. Coffman RL, Seymour BWP, Hudak S, et al. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989;245:308-310.
57. Gorczynski RM, Wojcik D. A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1, and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion. J Immunol 1994;152(4): 2011-2019.
58. Hosteller JS, Brummer E, Coffman RL, et al. Effect of anti-IL-4, interferon-gamma and an antifungal triazole (SCH 42427) in paracoccidioidomycosis: correlation of IgE levels with outcome. Clin Exp Immunol 1993;94(1):11-16.
59. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
60. Knox SJ, Levy R, Hodgkinson S, et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991;77:20-30.
61. Hale G, Dyer MI, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988;ii:1394-1399.
62. Mathieson PW, Cobbold SP, Hale G, et al. Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 1990;323:250-254.
63. Issacs JD, Watts RA, Hazleman BL, et al. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-752.
64. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet 1991;338: 320-321.
65. Nicolas JF, Chamchick N, Thivolet J, et al. CD4 antibody treatment of severe psoriasis. Lancet 1991;338:321.
66. Brown PS, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991;88:2663-2667.
67. Sears HF, Herlyn D, Steplewski I, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal carcinoma. J Biol Response Mod 1984;3: 138-150.
68. VanDerLubbe PA, Reiter C, Miltenburg AM, et al. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (CM-T412). Immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994;39:286-294.
69. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 1994;121: 1-5.
70. Yokota T, Milenic DE, Whitlow M. Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
71. Winter G, Milstein C. Man-made antibodies. Nature 1991;349:293-299.
72. Buchsbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 1995;55(23 Suppl):5729s-5732s.
73. Waldmann TA, The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993;14(6):264-270.
74. Friedman PN, McAndrew SJ, Gawlak SL, et al. BR96sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res 1993;53:334-339.
75. Weis W, Harwerth I, Mueller M, et al. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992;52: 6310-6317.
76. Drak J, Iwasawa N, Danishefsky S, Crothers DM. The carbohydrate domain of calicheamicin determines its sequence specificity for DNA clevage. Proc Natl Acad Sci USA 1991; 88:7464-7468.
77. Shalaby MR, Shepard HM, Presta L, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing HER2 protooncogene. J Exp Med 1992;179: 217-225.
78. Shalaby MR, Carter P, Maneval D, et al. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 1995; 74(2):185-192.
79. Zhu Z, Lewis GD, Carter P. Engineering high affinity humanized antip185HER2/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells. Int J Cancer 1995;62(3): 319-324.
80. Mezzanzanica D, Garrido MA, Neblock DS, et al. Human T lymphocytes targetted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in murine xenograft model. Cancer Res 1991;51: 5716-5721.
81. Amoroso AR, Clark JI, Litwin S, et al. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor. Cancer Res 1996;56(1):113-120.
82. Carter P, Ridway J, Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J Hematother 1995;4(5):463-470.
83. Tso JY, Wang SL, Levin W, Hakimi J. Preparation of a biospecific F(ab′)2 targeted to the human IL-2 receptor. J Hematother 1995;4(5):389-394.
84. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996;156(4): 1646-1653.
85. Choy EH, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996;39(1):52-56.
86. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995;38(11):1589-1594.
87. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995;38(9):1187-1193.
88. Graziano RF, Tempest PR, White P, et al. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J Immunol 1995; 155(10):4996-5002.
89. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55(23 Suppl):5935s-5945s.
90. Ceriani RL, Blank EW, Couto JR, Peterson JA. Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms. Cancer Res 1995;55(23): 5852s-5856s.
91. Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL. Radioimmunotherapy for breast cancer using escalating fractionated doses of 1311-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995;55(23 Suppl):5916s-5920s.
92. Litton MJ, Dohlsten M, Lando PA, et al. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 1996; 26(1):1-9.
93. Ellis JH, Barber KA, Tutt A, et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995; 155(2):925-937.
94. Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995;55(23 Suppl):5908s-5910s.
95. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55(23 Suppl):5899s-5907s.
96. Dhainaut JF, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics immune response and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995;23(9):1461-1469.
97. Chamow SM, Zhang D, Tan XY, et al. A humanized, bispecific immunoadhesion-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J Hematother 1995;4(5): 439-446.
98. Kaku S, Kawasaki T, Sakai Y, et al. Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys. Eur J Pharmacol 1995;279(2-3): 115-121.
99. Egan RW, Athwahl D, Chou CC, et al. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Immunol 1995;107(1-3):321-322.
100. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155: 1835-1840.
101. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-phase and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155: 1828-1834.
102. Burton DR, Barbas CS. Human monoclonal antibodies: recent achievements. Hosp Pract 1994;22: 71-82.